This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Celgene Corporation
Celgene Corporation, a prominent biopharmaceutical company headquartered in the United States, has established itself as a leader in the development of innovative therapies for cancer and inflammatory diseases. Founded in 1986, Celgene has achieved significant milestones, including the successful launch of groundbreaking treatments that have transformed patient care. Operating primarily in North America and Europe, Celgene focuses on areas such as oncology, immunology, and haematology. Its core products, including Revlimid and Pomalyst, are renowned for their unique mechanisms of action and efficacy in treating complex conditions. With a strong market position, Celgene has garnered recognition for its commitment to research and development, making substantial contributions to the biopharmaceutical landscape.
DitchCarbon Score
How does Celgene Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Celgene Corporation's score of 67 is higher than 81% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Celgene Corporation, headquartered in the US, currently does not have specific carbon emissions data available for recent years, as indicated by the absence of reported figures. The company is a current subsidiary of Bristol-Myers Squibb Company, which may influence its climate commitments and emissions reporting. As part of its corporate family, Celgene's climate initiatives and targets are likely aligned with those of Bristol-Myers Squibb. However, specific reduction targets or achievements for Celgene itself have not been disclosed. The company does not appear to have set its own Science-Based Targets Initiative (SBTi) reduction targets or other documented reduction initiatives. In the context of the pharmaceutical industry, companies are increasingly focusing on sustainability and reducing their carbon footprints. While Celgene has not provided specific emissions data or reduction commitments, it is essential to monitor the broader initiatives undertaken by its parent company, Bristol-Myers Squibb, which may include significant climate pledges and sustainability goals that could impact Celgene's operations and emissions in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 210,540,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 150,790,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 69,630,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Celgene Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
